Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.

Jonathan Poirier,Sophie Godemel,Aurélie Mourot,Solange Grunenwald,Harold J Olney,Xuan Kim Le,André Lacroix,Philippe Caron,Isabelle Bourdeau

The Journal of clinical endocrinology and metabolism（2023）

引用 0|浏览8

暂无评分

摘要

Mitotane therapy is frequently associated with new onset of central hypothyroidism with a prevalence of 95.5%. Most cases occurred in the first year of treatment. Partial or full recovery of thyroid function occurs in 65.4% of cases. This study supports the importance of systematic monitoring of TSH and free T4 levels during and following discontinuation of mitotane therapy.

查看译文

关键词

Adrenocortical cancer,hypothyroidism,mitotane

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要